Diffuse Large B Cell Lymphoma Clinical Trials in Cincinnati, Ohio

4 studies are recruiting for diffuse large b cell lymphoma in Cincinnati, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati Medical Center, Cincinnati, Ohio

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

2. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

   Locations

   5 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

3. Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

   This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati, Cincinnati, Ohio

   Locations

   4 in total

   Run by

   Newave Pharmaceutical Inc

   See if you can join NCT04775745 on ClinicalTrials.gov

4. Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

   This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati, Cincinnati, Ohio

   Locations

   45 in total

   Run by

   Kartos Therapeutics, Inc.

   See if you can join NCT04502394 on ClinicalTrials.gov